OBJECTIVE: To determine the incidence, characteristics, and evolution of sensorineural hearing loss (SNHL) in infants with a congenital cytomegalovirus infection (cCMV). STUDY DESIGN: In a prospective 10-year study, 14 021 unselected live-born infants were screened for cCMV by virus isolation in urine. Congenitally infected newborns were evaluated for SNHL during the first 5 years of life. RESULTS: A total of 74 of the 14 021 infants (0.53%) were congenitally infected; of these, 4 (5.4%) were symptomatic at birth. Hearing testing could be performed in 60 of the infants. SNHL was found in 21% of the asymptomatic and in 33% of symptomatic congenitally infected infants. Late-onset hearing loss was detected in 5%, progression in 11%, fluctuation in 16%, and improved hearing threshold in 18% of the infants with cCMV. SNHL was observed in 15% of infected infants born after a maternal primary infection, in 7% born after a maternal recurrent infection, and in 40% after a maternal infection of indeterminate timing. CONCLUSIONS: In our study population, 0.53% of the infants had cCMV infection, 22% of whom developed SNHL. Long-term follow up and repeated audiologic testing is needed, because progression, fluctuation, improvement, and late-onset hearing loss are important features of cCMV infection. The search for a neonatal screening program to detect all cCMV is worthwhile.
OBJECTIVE: To determine the incidence, characteristics, and evolution of sensorineural hearing loss (SNHL) in infants with a congenital cytomegalovirus infection (cCMV). STUDY DESIGN: In a prospective 10-year study, 14 021 unselected live-born infants were screened for cCMV by virus isolation in urine. Congenitally infected newborns were evaluated for SNHL during the first 5 years of life. RESULTS: A total of 74 of the 14 021 infants (0.53%) were congenitally infected; of these, 4 (5.4%) were symptomatic at birth. Hearing testing could be performed in 60 of the infants. SNHL was found in 21% of the asymptomatic and in 33% of symptomatic congenitally infected infants. Late-onset hearing loss was detected in 5%, progression in 11%, fluctuation in 16%, and improved hearing threshold in 18% of the infants with cCMV. SNHL was observed in 15% of infected infants born after a maternal primary infection, in 7% born after a maternal recurrent infection, and in 40% after a maternal infection of indeterminate timing. CONCLUSIONS: In our study population, 0.53% of the infants had cCMVinfection, 22% of whom developed SNHL. Long-term follow up and repeated audiologic testing is needed, because progression, fluctuation, improvement, and late-onset hearing loss are important features of cCMVinfection. The search for a neonatal screening program to detect all cCMV is worthwhile.
Authors: Suresh B Boppana; Shannon A Ross; Masako Shimamura; April L Palmer; Amina Ahmed; Marian G Michaels; Pablo J Sánchez; David I Bernstein; Robert W Tolan; Zdenek Novak; Nazma Chowdhury; William J Britt; Karen B Fowler Journal: N Engl J Med Date: 2011-06-02 Impact factor: 91.245
Authors: Aparecida Y Yamamoto; Marisa Marcia Mussi-Pinhata; Myriam de Lima Isaac; Fabiana R Amaral; Cristina G Carvalheiro; Davi C Aragon; Alessandra K da Silva Manfredi; Suresh B Boppana; William J Britt Journal: Pediatr Infect Dis J Date: 2011-12 Impact factor: 2.129
Authors: Philip R Krause; Stephanie R Bialek; Suresh B Boppana; Paul D Griffiths; Catherine A Laughlin; Per Ljungman; Edward S Mocarski; Robert F Pass; Jennifer S Read; Mark R Schleiss; Stanley A Plotkin Journal: Vaccine Date: 2013-10-13 Impact factor: 3.641